On August 28, 2018 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, reported that it will present a corporate overview at the 2018 Wells Fargo 13th Annual Healthcare Conference, being held on September 5-6 in Boston, MA (Press release, Aeglea BioTherapeutics, AUG 28, 2018, View Source [SID1234529097]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Wells Fargo Healthcare Conference
Aeglea BioTherapeutics Presentation Details
Date: Wednesday, September 5
Time: 10:50 am Eastern Time
Location: The Westin Copley Place, Boston, MA
Webcast: https://cc.talkpoint.com/well001/090518a_as/?entity=51_HGGS50C
To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The replay of the webcast will be available for 30 days thereafter.
Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aeglea’s Compensation Committee of its Board of Directors has granted non-qualified stock options to purchase an aggregate of 41,000 shares of Aeglea’s common stock to four new employees under Aeglea’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aeglea (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Aeglea, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The options have an exercise price of $10.28 or $10.54 per share, which is equal to the closing price of Aeglea’s common stock on August 24, 2018 or August 27, 2018, respectively. Each of the option awards vests as to 25% of the shares on the one-year anniversary of its grant, with the remainder of the shares vesting ratably over 36 months thereafter.